A randomized clinical trial for the efficacy and safety of Aliskiren and Nifedipine in novel coronavirus pneumonia (COVID-19) patients with hypertension

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032314

Enrollment

Unknown

Registered

2020-04-25

Start date

2020-03-01

Completion date

Unknown

Last updated

2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)N

Interventions

Group 2:Aliskiren with Standard Care

Group 1:Nifedipine with Standard Care

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. COVID-19 confirmed with SARS-COV-2 RNA detection; 2. Hypertension diagnosis; 3. Aged >=18 years.

Exclusion criteria

Exclusion criteria: 1. Allergic to Aliskiren or Nifedipine; 2. Pregnant or breastfeeding; 3. History of Aliskiren related angioedema; 4. Severe kidney disease or other organs failure need ICU care; 5. Cardiogenic shock or KOCK utricle; 6. Participation in anther clinical studies within 3 months of enrollment.

Design outcomes

Primary

Measure	Time frame
Improvement rate and time required for improvement (hours);Clinical status decrease by two levels;Pulmonary-related mortality;All-cause mortality;	—

Secondary

Measure	Time frame
Percentage of patients need for non-invasive ventilation or HFNC;Percentage of patients need for invasive ventilation;Negative conversion time of SARS-COV-2 nucleic acid test;Time for relieving fever;Time for improvement of respiratory symptoms;Length of hospitalization;Prevalence of severe adverse reactions;	—

Countries

China

Contacts

Public ContactFengming Luo

West China Hospital, Sichuan University

luofengming@hotmail.com+86 18980601355

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026